An algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
Many investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Patients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Anti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.
A number of macular conditions either mimic or share characteristic findings of age-related macular degeneration (AMD). These resemblances can result in tough clinical decisions and misdiagnosis. Although genetic testing can be helpful, tests are limited by both their efficacy and accuracy.